Comparing the next-generation triple agonist with the established GLP-1 standard
| Feature | Retatrutide | Semaglutide |
|---|---|---|
| Brand Names | LY3437943 (investigational) | Ozempic, Wegovy |
| Developer | Eli Lilly | Novo Nordisk |
| Mechanism | GLP-1 + GIP + Glucagon (triple) | GLP-1 only (single) |
| FDA Status | Not approved (Phase 3 trials) | FDA approved |
| Dosing Frequency | Once weekly | Once weekly |
| Starting Dose | 0.5 mg/week | 0.25 mg/week |
| Maximum Studied Dose | 12 mg/week | 2.4 mg/week |
| Weight Loss (Phase 2) | Up to ~24% body weight | ~15-16% body weight |
| Half-Life | ~6 days | ~7 days |
| Glucagon Component | Yes (increases energy expenditure) | No |
| Years of Safety Data | <3 years (trial data only) | 7+ years real-world data |
| Availability | Research suppliers only | Pharmacies + compounding |
Retatrutide represents a potential leap forward in incretin-based therapy by adding a third receptor target: the glucagon receptor. While semaglutide suppresses appetite through GLP-1 activation alone, retatrutide adds glucagon receptor agonism which may increase energy expenditure and fat oxidation on top of appetite reduction.
Phase 2 trial data showed participants on retatrutide achieved greater weight reduction compared to historical semaglutide results, though direct head-to-head trials have not been completed. The trade-off is that retatrutide has far less safety data and is not yet FDA approved.
Semaglutide remains the proven, FDA-approved option with extensive real-world safety data. Retatrutide shows promise but is still investigational. For most people, semaglutide or tirzepatide are the appropriate current choices. Retatrutide via research suppliers carries additional risks related to purity, dosing accuracy, and lack of medical oversight.
The third target is the interesting part, and it is initially counterintuitive. Glucagon is the hormone that raises blood glucose, which sounds like the opposite of what a metabolic therapy should do. The rationale is that glucagon receptor agonism also increases energy expenditure and promotes hepatic fat mobilization, and that pairing it with strong GLP-1 and GIP activity offsets the glucose-raising effect while keeping the metabolic-rate benefit.
That changes the shape of the mechanism. Semaglutide works essentially by reducing energy intake: less appetite, slower gastric emptying, earlier satiety. Retatrutide is designed to reduce intake and raise expenditure at the same time. If that holds up in Phase 3, it is a meaningfully different lever rather than a stronger version of the same one.
It also means the side effect profile may not simply be "semaglutide but more." Adding a third receptor pathway introduces effects that single and dual agonists do not have, and reported findings in trials have included increases in heart rate. This is one of the specific things Phase 3 is designed to characterize, and it is a reason the safety picture is not yet settled.
The headline figure of roughly 24 percent body weight reduction is real, but it deserves careful reading before it is compared against semaglutide's 15 to 16 percent.
Those numbers come from different trials, with different participant populations, different durations, and different endpoints. That is a cross-trial comparison, not a head-to-head result. Cross-trial comparisons routinely flatter the newer compound, because trial design, baseline characteristics, and dropout handling all differ. No completed head-to-head trial of retatrutide against semaglutide exists. Until one does, the honest statement is that retatrutide's Phase 2 results are promising, not that it outperforms semaglutide by eight percentage points.
There is also a phase difference worth weighing. Phase 2 trials are smaller and shorter, and they are designed to find a dose and detect a signal rather than to establish safety at scale. Effect sizes commonly shrink between Phase 2 and Phase 3 as populations broaden. Semaglutide's figures come from large completed Phase 3 programs plus years of post-approval use.
Because retatrutide is not approved, it cannot be obtained through a pharmacy. Anything available is sold as a research chemical, and that distinction carries consequences that are easy to underrate.
Research-supply material is not subject to the identity, purity, sterility, and concentration verification that governs pharmaceutical manufacturing. A vial labeled 10 mg has not been independently confirmed to contain 10 mg, to contain retatrutide specifically, or to be free of contaminants. Certificates of analysis vary widely in rigor and are sometimes supplied by the seller rather than an independent lab.
That uncertainty compounds with the dosing question. Reconstitution math assumes the vial contains what the label says. If the actual content differs, every downstream calculation is wrong by the same factor, and no calculator can detect that. This is the practical reason the comparison above is framed as educational reference rather than guidance.
Need the broader GLP-1 reference set first? Start with the GLP-1 calculator hub, then move into the individual calculators and comparison pages.
Calculate your dose: Retatrutide calculator | Semaglutide calculator
This comparison is educational and should be read with product labeling, current clinical literature, and professional guidance where appropriate.